Osmotica Pharmaceutical Announces Initiation of Phase III Studies With Arbaclofen ER Tablets

Published: Dec 10, 2012

WILMINGTON, N.C.--(BUSINESS WIRE)--Osmotica Pharmaceutical announced today that recruitment has begun for a Phase 3 clinical trial designed to assess the safety and efficacy of Arbaclofen Extended Release Tablets in patients with spasticity due to multiple sclerosis (MS). Spasticity is one of the more common symptoms of MS and refers to involuntary muscle stiffness or spasms. It occurs in an estimated 80 percent of people with this disease. The primary objectives of the study are to demonstrate the efficacy of Arbaclofen Extended Release Tablets range of doses for treatment.

Back to news